Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mountain High Appoints Leading Cannabis Authority Dr. Robert Melamede Ph.D. as Scientific Advisor

BIOGY, C.ENRT

DENVER, CO--(Marketwired - Apr 16, 2014) - Mountain High Acquisitions Corp. (OTCQB: MYHI) ("Mountain High" or the "Company"), is pleased to announce that leading cannabis authority Dr. Robert Melamede, Ph.D. has joined the Advisory Board of the Company.

"Dr. Melamede is a visionary and a pioneer in the field of medicinal cannabis research, so we are greatly honored that he has agreed to join our team as Scientific Advisor," stated Mr. Alan Smith, President of Mountain High Acquisitions Corp. "His years of leading scientific research and cannabis advocacy have earned him a reputation as a vital industry source of knowledge, opinion, industry contacts, and inspiration. As our new Scientific Advisor, we are confident that he will be instrumental in helping us achieve our corporate objectives. In particular, his advice will be invaluable as we provide additional complementary services to current and future cannabis growing tenants and strategically develop our properties for use by the cannabis industry."

Dr. Robert Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede is the President of Cannabis Science, Inc. (OTCQB: CBIS), a medical cannabis research and development company, and an advisor to Enertopia Corporation (OTCQB: ENRT), a company with a medical marijuana cultivation joint venture. Dr. Melamede also serves on the Editorial Board of The Journal of the International Association for Cannabis as Medicine, the Scientific Advisory Board of Americans for Safe Access, Sensible Colorado, Scientific Advisor for Cannabis Therapeutics, as well as a variety other of state dispensaries and marijuana patient advocacy groups. Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede retired as Chairman of the Biology Department at University of Colorado, Colorado Springs, in 2005, where he continues to teach and research cannabinoids, cancer, and DNA repair. 

About Mountain High Acquisitions Corp. (MYHI)

Mountain High Acquisitions Corp. is a strategic real estate holding company whose primary focus is the acquisition and development of commercial properties to be leased and utilized by the marijuana industry. Mountain High's current portfolio includes three Colorado properties zoned for commercial marijuana cultivation: Isabelle, Madison, and Pueblo. 

Disclaimer/Safe Harbor: This Mountain High Acquisitions Corp. news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all. The Company does not and will not grow, harvest, distribute, or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future.

Investor/Media Contact:

Mountain High Acquisitions Corp.
Investor Relations
(844) 686-0420 (Toll-free)
E-mail: Email Contact
Website: www.mountainhighac.com

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today